Paul McCormac - Nov 2, 2023 Form 3 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Technical Officer
Signature
/s/ Jenny Robertson, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Nov 2, 2023
Transactions value $
$0
Form type
3
Date filed
11/2/2023, 09:38 PM
Next filing
Nov 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LXEO Common Stock 14.2K Nov 2, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding LXEO Series B convertible preferred stock Nov 2, 2023 Common Stock 2.74K Direct F1
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 46K $2.33 Direct F2
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 112K $4.87 Direct F3
holding LXEO Employee Stock Option (right to buy) Nov 2, 2023 Common Stock 9.44K $11.02 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B convertible preferred stock is convertible into Common Stock on a 1-for-10.594230 at any time at the Reporting Person's election, and automatically upon the closing of the Issuer's initial public offering without payment or further consideration. Excludes shares of Common Stock issuable upon the closing of the Issuer's initial public offering pursuant to anti-dilution adjustment provisions of the Series B convertible preferred stock. The shares have no expiration date.
F2 25% of the shares underlying the option vested on March 22, 2022, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F3 25% of the shares underlying the option vested on August 11, 2022, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
F4 25% of the shares underlying the option shall vest on August 22, 2024, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney